NovoMix 30 | Annual Sales Report | Pharmacompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

NovoMix 30
Annual Reports

AMI Lifesciences is Driven by Chemistry. Powered by People.

Contact Supplier

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

Contact Supplier

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

Quotient Sciences- Molecule to Cure. Fast.

Contact Supplier

pharmacompass-2-m-2025-08-25

NovoMix 30

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

4 API Suppliers, 4 USDMF, 1 NDC API, $ API Reference Price

4 API Suppliers
4 USDMF
1 NDC API
$ API Reference Price

DEVELOPMENTS

167 Drugs in Development

167 Drugs in Development

FINISHED DOSAGE FORMULATIONS

62 FDF Dossiers, 14 FDA Orange Book, 23 Europe, 11 Canada, 4 Australia, 10 South Africa

62 FDF Dossiers
14 FDA Orange Book
23 Europe
11 Canada
4 Australia
10 South Africa

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Rochem International Inc, 13 SPI Pharma, 1 Gangwal Healthcare, 1 Pfanstiehl, 1 Capital Farma, 1 Kirsch Pharma, 5 Actylis, 1 BASF, 2 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 1 Kerry, 2 Microlex e.U, 2 Pluviaendo, 3 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

2 EUROAPI
1 Rochem International Inc
13 SPI Pharma
1 Gangwal Healthcare
1 Pfanstiehl
1 Capital Farma
1 Kirsch Pharma
5 Actylis
1 BASF
2 Gangwal Chemicals
1 Ingredion Pharma Solutions
1 Kerry
2 Microlex e.U
2 Pluviaendo
3 Roquette
1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
1 Shijiazhuang Huaxu Pharmaceutical
1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

18 Fillers, Diluents & Binders, 13 Parenteral, 12 Chewable & Orodispersible Aids, 10 Direct Compression, 10 Taste Masking, 7 Disintegrants & Superdisintegrants, 3 Co-Processed Excipients, 3 Granulation, 2 Topical, 1 Thickeners and Stabilizers, 1 Solubilizers, 1 Film Formers & Plasticizers

18 Fillers, Diluents & Binders
13 Parenteral
12 Chewable & Orodispersible Aids
10 Direct Compression
10 Taste Masking
7 Disintegrants & Superdisintegrants
3 Co-Processed Excipients
3 Granulation
2 Topical
1 Thickeners and Stabilizers
1 Solubilizers
1 Film Formers & Plasticizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 38 News #PharmaBuzz

1 Data Compilation #PharmaFlow
38 News #PharmaBuzz

GLOBAL SALES INFORMATION

14 US Medicaid Prescriptions, 23 Regulatory FDF Prices, 49 Annual Reports

14 US Medicaid Prescriptions
23 Regulatory FDF Prices
49 Annual Reports

MARKET PLACE

3 APIs, 2 FDF Dossiers

3 APIs
2 FDF Dossiers

PATENTS & EXCLUSIVITIES

14 Health Canada Patents

14 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 1 Others

1 EDQM
1 Others

$ API Ref.Price (USD/KG) : 86,022 Xls

Filters

Reset all filters

Filters

FILTER :

filter Product Reset all filters

49 All

01 7Fiasp

02 6NovoMix

03 1NovoMix/NovoLog Mix

04 6NovoRapid

05 1NovoRapid/NovoLog

06 2Novomix/Novolog Mix

07 2Novorapid/Novolog

08 11Ryzodeg

09 8Tresiba

10 5Xultophy

List of Suppliers

Product Main Page

01

Brand Name : NovoRapid

Pharmaconex

Not Confirmed

Brand Name : NovoRapid

Pharmaconex

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Novo Nordisk

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 2,753

2019 Revenue in Millions : 2,937

Growth (%) : -6

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Brand Name : Xultophy

Insulin Degludec, Insulin Aspart

Pharmaconex

Not Confirmed

Brand Name : Xultophy

Pharmaconex

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Novo Nordisk

Insulin Degludec, Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 398

2019 Revenue in Millions : 359

Growth (%) : 11

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Brand Name : Ryzodeg

Pharmaconex

Not Confirmed

Brand Name : Ryzodeg

Pharmaconex

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Novo Nordisk

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 210

2019 Revenue in Millions : 162

Growth (%) : 30

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Brand Name : Fiasp

Pharmaconex

Not Confirmed

Brand Name : Fiasp

Pharmaconex

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Novo Nordisk

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 225

2019 Revenue in Millions : 202

Growth (%) : 11

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Brand Name : Tresiba

Insulin Degludec, Insulin Aspart

Pharmaconex

Not Confirmed

Brand Name : Tresiba

Pharmaconex

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Novo Nordisk

Insulin Degludec, Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 1,459

2019 Revenue in Millions : 1,506

Growth (%) : -3

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Brand Name : Ryzodeg

Insulin Degludec, Insulin Aspart

Pharmaconex

Not Confirmed

Brand Name : Ryzodeg

Pharmaconex

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Novo Nordisk

Insulin Degludec, Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 210

2019 Revenue in Millions : 162

Growth (%) : 30

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

Brand Name : NovoMix

Biphasic Insulin Aspart

Pharmaconex

Not Confirmed

Brand Name : NovoMix

Pharmaconex

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Novo Nordisk

Biphasic Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 1,567

2019 Revenue in Millions : 1,559

Growth (%) : 1

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

Brand Name : Ryzodeg

Insulin Degludec, Insulin Aspart

CPHI Shenzhen

Not Confirmed

Brand Name : Ryzodeg

CPHI Shenzhen

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Novo Nordisk

Insulin Degludec, Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 261

2020 Revenue in Millions : 207

Growth (%) : 33

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

Brand Name : Fiasp

Pharmaconex

Not Confirmed

Brand Name : Fiasp

Pharmaconex

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Novo Nordisk

Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 266

2020 Revenue in Millions : 222

Growth (%) : 26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

Brand Name : Tresiba

Insulin Degludec, Insulin Aspart

CPHI Shenzhen

Not Confirmed

Brand Name : Tresiba

CPHI Shenzhen

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Novo Nordisk

Insulin Degludec, Insulin Aspart

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 1,483

2020 Revenue in Millions : 1,435

Growth (%) : 8

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2
3
Last

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!